CAJ | 학술논문

目的：分析尤瑞克林治疗青年急性脑梗死(ACI)近期临床疗效及安全性。方法将332例年龄18岁~45岁 ACI住院患者,随机分为两组。治疗组232例,给予注射用尤瑞克林0.15单位,同时给予缺血性卒中的基础治疗；对照组100例,给予相同缺血性卒中基础用药,生理盐水静脉注射。按中国缺血卒中分型(Chinese ischemic stroke subclassi cation,CISS)病因和发病机制分型,观察分析两组患者治疗前、治疗后14 d的美国国立卫生研究院卒中量表(NIHSS)评分与不良反应发生情况。结果两组患者治疗后14 d美国国立卫生研究院卒中量表(NIHSS)评分均较治疗前明显改善(P<0.05)；治疗组评分明显低于对照组(P<0.05)。CISS分型中,除心源性卒外,治疗组中其他4种病因患者的(NIHSS)评分减少程度均优于对照组的相同类型(P<0.05)。两组均未发现严重不良反应。结论尤瑞克林能安全有效改善青年 ACI不同病因患者的神经功能缺失。
목적：분석우서극림치료청년급성뇌경사(ACI)근기림상료효급안전성。방법장332례년령18세~45세 ACI주원환자,수궤분위량조。치료조232례,급여주사용우서극림0.15단위,동시급여결혈성졸중적기출치료；대조조100례,급여상동결혈성졸중기출용약,생리염수정맥주사。안중국결혈졸중분형(Chinese ischemic stroke subclassi cation,CISS)병인화발병궤제분형,관찰분석량조환자치료전、치료후14 d적미국국립위생연구원졸중량표(NIHSS)평분여불량반응발생정황。결과량조환자치료후14 d미국국립위생연구원졸중량표(NIHSS)평분균교치료전명현개선(P<0.05)；치료조평분명현저우대조조(P<0.05)。CISS분형중,제심원성졸외,치료조중기타4충병인환자적(NIHSS)평분감소정도균우우대조조적상동류형(P<0.05)。량조균미발현엄중불량반응。결론우서극림능안전유효개선청년 ACI불동병인환자적신경공능결실。
Objective To evaluate the short term clinical efficacy and safty of human urinary kal i dinogenase in the treatment of of the young patients with acute cerebral infarction (ACI)according to Chinese Ischemic Stroke Subclassi cation(CISS).Methods Three hundreds and thirty two patients of 18 to 45 years old with ACI were divided randomly into two groups:Treatment group(n= 232) treated by 0.15 PNA of human urinary kal i dinogenase on the basis of basic treatment,and control group (n= 100)treated by basic treatment plus saline solution.The NIH Stroke Scale (NIHSS)scores were analyzed linking to CISS before and after 14 days of treat-ment.The treatment adverse reaction was abserved.Results The NIHSS scores of two groups after treatment were improved com-paraed with that before treatment(P<0.05).The scores in treatment group were significantly lower than that in control group(P<0.05).The NIHSS scores reduction level of the other 4 CISS types of stroke besides cardiogenic cerebral embolism in the treatment group exceeded that of the same stroke types in the control group (P<0.05).Serious adverse reaction were not found in both groups.Conclution Human urinary kal idinogenase can safrly improve the neurologic impairment in the young ACI patients with dif-ferent etiology.